CA3086535A1 - Crystalline forms of nicotinamide riboside chloride - Google Patents
Crystalline forms of nicotinamide riboside chloride Download PDFInfo
- Publication number
- CA3086535A1 CA3086535A1 CA3086535A CA3086535A CA3086535A1 CA 3086535 A1 CA3086535 A1 CA 3086535A1 CA 3086535 A CA3086535 A CA 3086535A CA 3086535 A CA3086535 A CA 3086535A CA 3086535 A1 CA3086535 A1 CA 3086535A1
- Authority
- CA
- Canada
- Prior art keywords
- crystalline form
- subject
- administering
- solution
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609512P | 2017-12-22 | 2017-12-22 | |
| US62/609,512 | 2017-12-22 | ||
| PCT/US2018/066769 WO2019126482A1 (en) | 2017-12-22 | 2018-12-20 | Crystalline forms of nicotinamide riboside chloride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3086535A1 true CA3086535A1 (en) | 2019-06-27 |
Family
ID=66993830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3086535A Pending CA3086535A1 (en) | 2017-12-22 | 2018-12-20 | Crystalline forms of nicotinamide riboside chloride |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11414407B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3727400A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021506898A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112020363A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3086535A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019126482A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11129843B2 (en) | 2017-04-24 | 2021-09-28 | Elysium Health, Inc. | Treating and preventing kidney damage |
| EP3727400A4 (en) | 2017-12-22 | 2021-10-20 | Elysium Health, Inc. | CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE |
| JP7675061B2 (ja) | 2019-07-19 | 2025-05-12 | バイオシント アクチェンゲゼルシャフト | ニコチンアミドリボフラノシド塩の製造方法、ニコチンアミドリボフラノシド塩自体、およびその使用 |
| CN111454311B (zh) | 2020-04-03 | 2021-10-19 | 深圳市迪克曼科技开发有限公司 | 烟酰胺核糖的有机酸盐及其组合物与制备方法 |
| CN111808156A (zh) * | 2020-07-15 | 2020-10-23 | 许昌远志生物科技有限公司 | 一种β-烟酰胺核糖氯化物的晶型1A、晶型1B及其制备方法 |
| EP4727544A2 (en) | 2023-06-14 | 2026-04-22 | Chromadex Inc. | Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1190080A (en) | 1966-08-08 | 1970-04-29 | Kyowa Hakko Kogyo Company Ltd | Process for producing Nicotinamide Adenine Dinucleotide |
| US3728111A (en) | 1971-09-21 | 1973-04-17 | Asea Ab | Method of manufacturing billets from powder |
| EP0981534B1 (en) | 1997-02-06 | 2006-05-03 | Inspire Pharmaceuticals, Inc. | Dinucleotides and their uses |
| GB9712370D0 (en) | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
| JP2005502580A (ja) | 2000-12-15 | 2005-01-27 | フアーマセツト・リミテツド | フラビウィルス感染治療用抗ウィルス薬 |
| US7179791B2 (en) | 2001-01-11 | 2007-02-20 | Duke University | Inhibiting GS-FDH to modulate NO bioactivity |
| JP3748536B2 (ja) | 2001-02-09 | 2006-02-22 | 三共株式会社 | ピリミジンヌクレオシド誘導体の結晶 |
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| US20050020587A1 (en) | 2003-07-25 | 2005-01-27 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| US8114626B2 (en) | 2004-02-10 | 2012-02-14 | Trustees Of Dartmouth College | Yeast strain and method for using the same to produce nicotinamide riboside |
| EP1723227A4 (en) | 2004-02-10 | 2007-09-19 | Dartmouth College | NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE |
| CN1964627B (zh) | 2004-06-04 | 2011-10-19 | 华盛顿大学 | 治疗神经病变的方法和组合物 |
| ES2430569T3 (es) | 2005-02-18 | 2013-11-21 | Astrazeneca Ab | Compuestos antibacterianos derivados de piperidina |
| EP2805719A1 (en) | 2005-03-30 | 2014-11-26 | Glaxosmithkline LLC | Nicotinamide riboside and analogues thereof |
| US20070149466A1 (en) | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| WO2007061798A2 (en) | 2005-11-18 | 2007-05-31 | Cornell Research Foundation, Inc. | Nicotinoyl riboside compositions and methods of use |
| US20070248590A1 (en) | 2005-12-02 | 2007-10-25 | Sirtris Pharmaceuticals, Inc. | Modulators of CDC2-like kinases (CLKS) and methods of use thereof |
| WO2007136744A1 (en) | 2006-05-19 | 2007-11-29 | The Johns Hopkins University | Crystal structure of a substrate complex of nampt/pbef/visfatin |
| JP2010513458A (ja) | 2006-12-19 | 2010-04-30 | ファイザー・プロダクツ・インク | H−pgdsの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンd2の仲介による疾患を治療するためのその使用 |
| CA2676609A1 (en) | 2007-01-26 | 2008-07-31 | Washington University | Methods and compositions for treating neuropathies |
| EP2307378A1 (en) | 2008-06-18 | 2011-04-13 | Pfizer Limited | Nicotinamide derivatives |
| US20100015072A1 (en) | 2008-06-30 | 2010-01-21 | Christopher Polla | Topical Compositions Comprising Isonicotinamide |
| CL2009002206A1 (es) | 2008-12-23 | 2011-08-26 | Gilead Pharmasset Llc | Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales. |
| JP5739415B2 (ja) | 2009-05-12 | 2015-06-24 | ブリストル−マイヤーズ スクウィブ カンパニー | (S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用 |
| WO2011005289A2 (en) | 2009-06-23 | 2011-01-13 | President And Fellows Of Harvard College | Methods and kits for measuring enzyme activity |
| WO2011011721A2 (en) | 2009-07-24 | 2011-01-27 | Amazentis Sa | Compounds, compositions and methods for protecting brain health in neurodegenerative disorders |
| US8507251B2 (en) | 2009-09-28 | 2013-08-13 | Robert J. Greenstein | Medium and method for culturing Mycobacterium avium subspecies paratuberculosis |
| WO2011081942A1 (en) | 2009-12-14 | 2011-07-07 | Cornell University | Activation and activators of sirt5 |
| EP2464249B1 (de) | 2010-03-29 | 2013-03-13 | Johannes Huber | Konzentrationssteigerndes getränk |
| US8481711B2 (en) | 2010-07-06 | 2013-07-09 | Hidenori Kamanishi | Neurite outgrowth agent |
| WO2012114204A2 (en) | 2011-02-15 | 2012-08-30 | Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto | Methods of treating mitochondrial dysfunction |
| US20120107888A1 (en) | 2011-02-17 | 2012-05-03 | Qteros, Inc. | Modulation of fermentation products through vitamin supplementation |
| US20120328526A1 (en) | 2011-06-27 | 2012-12-27 | University Of Maryland, Baltimore | Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof |
| EP3345901A3 (en) | 2011-06-29 | 2018-09-12 | President and Fellows of Harvard College | Small molecules as antiaging agents |
| US20140256760A1 (en) | 2012-07-09 | 2014-09-11 | Noglo Llc | Reduction or prevention of alcohol reaction with dietary supplements |
| EP2869717B8 (en) | 2012-07-09 | 2018-07-25 | NoGlo, Inc. | Prevention of alcohol reaction with dietary supplements |
| EP2872128B1 (en) | 2012-07-16 | 2020-02-19 | Cornell University | Nicotinamide riboside to treat hearing loss |
| WO2014059029A1 (en) | 2012-10-09 | 2014-04-17 | President And Fellows Of Harvard College | Treatment of age-related and mitochondrial diseases by inhibition of hif-1 alpha function |
| WO2014111906A1 (en) | 2013-01-21 | 2014-07-24 | Ecole Polytechnique Federale De Lausanne (Epfl) | Bioluminescence imaging of small biomolecules |
| SG11201507046UA (en) | 2013-03-15 | 2015-10-29 | Nusirt Sciences Inc | Leucine and nicotinic acid reduces lipid levels |
| GB201313465D0 (en) | 2013-07-29 | 2013-09-11 | Queens University Of The Belfast | Methods of preparing nicotinamide riboside and derivatives thereof |
| WO2015061512A1 (en) | 2013-10-24 | 2015-04-30 | The Procter & Gamble Company | Skin lightening cosmetic compositions and methods |
| WO2015064988A1 (ko) | 2013-10-29 | 2015-05-07 | 한림대학교 산학협력단 | 니코틴아마이드 라이보사이드를 유효성분으로 포함하는 패혈증 치료 또는 예방용 약제학적 조성물 |
| JP6509844B2 (ja) | 2013-10-30 | 2019-05-08 | クロマデックス, インコーポレイテッドChromaDex, Inc. | 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物 |
| BR112016010422B1 (pt) | 2013-11-12 | 2021-08-31 | Ortho-Nutra, Llc | Suplemento dietético e método de tratamento para melhorar o desempenho ou energia física em um indivíduo |
| WO2015099842A1 (en) | 2013-12-23 | 2015-07-02 | Abbott Laboratories | Hot beverage fortifier |
| JP2017511304A (ja) | 2014-03-13 | 2017-04-20 | ソーク インスティチュート フォー バイオロジカル スタディーズ | フェキサラミン類似体ならびに作製方法および使用方法 |
| US20150297508A1 (en) | 2014-04-21 | 2015-10-22 | William Andriette | Topical Formulation to Enhance Genital Sensation and Function |
| US10316054B2 (en) | 2014-06-02 | 2019-06-11 | Glaxosmithkline Intellectual Property (No. 2) Limited | Preparation and use of crystalline beta-D-nicotinamide riboside |
| WO2016011360A1 (en) | 2014-07-17 | 2016-01-21 | The Scripps Research Institute | Methods and compositions for enhancing cancer therapy |
| CA2956163C (en) * | 2014-07-24 | 2023-01-10 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| ES2963057T3 (es) * | 2015-03-09 | 2024-03-25 | Grace W R & Co | Forma cristalina de ribósido de nicotinamida |
| CN109562104A (zh) | 2016-04-14 | 2019-04-02 | 可劳迈戴斯有限公司 | 烟酰胺核苷、烟酸核苷、烟酰胺单核苷酸、和烟碱基化合物衍生物在婴儿配方中的用途 |
| WO2017218580A1 (en) * | 2016-06-14 | 2017-12-21 | Rejuvenation Therapeutics Corporation | Synthetic methods for the preparation of nicotinamide riboside and related compounds |
| NZ803738A (en) | 2016-11-11 | 2024-05-31 | Chromadex Inc | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
| EP3727400A4 (en) | 2017-12-22 | 2021-10-20 | Elysium Health, Inc. | CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE |
| JP7675061B2 (ja) | 2019-07-19 | 2025-05-12 | バイオシント アクチェンゲゼルシャフト | ニコチンアミドリボフラノシド塩の製造方法、ニコチンアミドリボフラノシド塩自体、およびその使用 |
| CN111808156A (zh) | 2020-07-15 | 2020-10-23 | 许昌远志生物科技有限公司 | 一种β-烟酰胺核糖氯化物的晶型1A、晶型1B及其制备方法 |
-
2018
- 2018-12-20 EP EP18892817.0A patent/EP3727400A4/en not_active Withdrawn
- 2018-12-20 WO PCT/US2018/066769 patent/WO2019126482A1/en not_active Ceased
- 2018-12-20 US US16/955,412 patent/US11414407B2/en active Active
- 2018-12-20 CN CN201880090063.7A patent/CN112020363A/zh active Pending
- 2018-12-20 JP JP2020534265A patent/JP2021506898A/ja active Pending
- 2018-12-20 CA CA3086535A patent/CA3086535A1/en active Pending
-
2022
- 2022-08-12 US US17/887,060 patent/US12043616B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3727400A1 (en) | 2020-10-28 |
| WO2019126482A1 (en) | 2019-06-27 |
| US11414407B2 (en) | 2022-08-16 |
| US12043616B2 (en) | 2024-07-23 |
| US20230063175A1 (en) | 2023-03-02 |
| CN112020363A (zh) | 2020-12-01 |
| US20210094936A1 (en) | 2021-04-01 |
| EP3727400A4 (en) | 2021-10-20 |
| JP2021506898A (ja) | 2021-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12043616B2 (en) | Crystalline forms of nicotinamide riboside chloride | |
| US11629163B2 (en) | Methods of synthesizing nicotinamide riboside | |
| CN107428791B (zh) | 烟酰胺核苷的结晶形式 | |
| JP6289659B2 (ja) | 五環トリテルペン構造修飾化合物とその調製方法及び応用 | |
| CA3172203A1 (en) | Process, compositions, and crystalline forms of substituted pyridinone-pyridinyl compounds | |
| US20250145657A1 (en) | Non-hormonal steroid modulators of nf-kappa beta for treatment of disease | |
| EP3033350A1 (en) | Progesterone phosphate analogs and uses related thereto | |
| CA2973383A1 (en) | Treatment of filarial diseases | |
| FR2549834A1 (fr) | Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques | |
| WO2024155842A1 (en) | Compositions useful for modulating splicing | |
| JP2015532263A (ja) | ウリプリスタール酢酸エステルの結晶多形 | |
| US9776989B2 (en) | Chromone alkaloid dysoline for the treatment of cancer and inflammatory disorders | |
| CA2726419A1 (en) | Trans-chinnamic acid derivative and preparation method and the use thereof | |
| CN112661692A (zh) | 一种异吲哚啉衍生类化合物、制备方法及减肥应用 | |
| WO2018172496A1 (en) | Compounds and compositions for use in treating psoriasis | |
| DE602004013453T2 (de) | Thiomorpholinosteroidverbindungen, deren verwendung zur herstellung von die meiose steuernden medikamenten und verfahren zu deren herstellung | |
| WO2025140361A1 (zh) | 甘草次酸衍生物及其用途 | |
| CN117999072A (zh) | β肾上腺素能激动剂和其使用方法 | |
| WO1990007509A1 (fr) | Derives de diazabicycloalcane | |
| JPH08104639A (ja) | Il−5産生抑制剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231214 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241122 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241122 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241122 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250127 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250527 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250604 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250724 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250724 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251027 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251126 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251126 |